Zymeworks grabs Theravance in $929 million respiratory buyout
Zymeworks has closed its $929 million takeover of Theravance Biopharma, picking up a commercial COPD drug and a set of royalty streams that reshape its revenue mix.
Royalty Pharma 1 article
The company-level profile of Royalty Pharma is built around biotechnology capital partnership, with biopharmaceutical royalties representing a second durable component of its economics. Its portfolio identity is shaped by life science royalty acquisition and drug royalty monetization, with biopharma funding solutions showing the connection between contractual economics and biotechnology products. GenoMethods separates royalty ownership from the underlying medicines and developers; the business model of Royalty Pharma also includes non-dilutive pharmaceutical financing.